$24.15
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
Country

US

CEO

Dr. Albert Bourla

IPO date

1944

Employees

75,000

ISIN

US7170811035

Key stats

Open

$24.11

Volume

38.19M

Market cap

$137.39B

Prev. close

$24.05

Impl / hst vl

-

Open interest

$0.00

$24.09

Day’s Range

$24.16

$23.62

52W Range

$28.75

Valuation

44
Valuation score
Fairly Valued
P/E
18.29
P/S
2.16
P/B
1.52
Current ratio
1.25
Debt / Equity
0.70
ROE
8.37%
Gross margin
76.42%
Income growth
-263.05%
FCF growth
-51.62

Sep

1

Dividends

The next payment date will be Sep 1, 2026

Div. per Share

$0.43

Div. Yield

1.79%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 19 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$29.61
The top 31 analysts forecasts that 12-month price may increase by 22.60%, with a low of $24.24 and a high of $37.80
$24.24
Low
$29.61
Avg
$37.80
High
Current price

Earnings

Q1 ‘26 revenue
$14.45B
Q1 ‘26 net income
$2.69B
Revenue
Net income
Previous EPS
$0.75
Estimate EPS
$0.69
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply